drugset
drugset / Trial / NCT02109146

Postoperative TACE(Transhepatic Arterial Chemotherapy And Embolization) for Patients With Hepatocellular Carcinoma

NCT02109146 ↗

Phase 3 Completed 332 enrolled Zhejiang University
RandomizedParallel-groupOpen-labelTreatment

Summary

1. Hepatocellular carcinoma (HCC) is the most common primary malignancy of liver, representing the third leading cause of cancer-related death worldwide. 2. Its overall dismal prognosis is a result of high incidence rates of metastasis and postoperative recurrence, in particular the intrahepatic recurrence. 3. TACE is the most widely used primary treatment for unresectable HCC. It was also used as the optional treatment for relapsed disease. However, the efficacy of TACE used as adjuvant therapy following hepatectomy remains controversial.

Timeline

Start
2014-03-26
Primary completion
2023-05-13
Completion
2023-05-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Epirubicin Small molecule 40 mg Other
Subject Oxaliplatin Small molecule 150 mg Other
Background lipiodol Unknown 3 ml Other
Background lipiodol Unknown 5 ml Other

Indications

hepatocellular carcinoma